JUST IN: The first human trial of "reverse-aging" drugs has started.
Life Biosciences dosed the first patients with ER-100, a drug built to make damaged eye cells act younger.
The method is called cellular reprogramming. If it works, the idea moves beyond the eye. Liver disease. Nerve damage. Brain decline.
Longevity pulled in $8.5 billion in 2024 alone. The market's headed for $314 billion by 2030.



